March Roadshows, page-263

@Taureanbull

completly IMO i think they wont get any advantages from the previous ongoing trials... I got the opinion from the roadshow (and previous commentary) that Oncarlytics is having to jump through greater hoops to get the IND approval... It is completely foreign to the FDA, an oncolytic virus expressing CD19... the timeline appears to have slipped... no commentary from mgmt on approval date... Yuman only said it will be in trials "this year" but, said when was Leslie's job..."we've got top dot our I's and cross our t's, and rightfully so"

if it is getting assessed harder, then i can't imagine it getting any benefit on the lower doses from CF33 learnings... hope to be wrong, but, don't think it will...

but, i can wait... market, maybe not